目的 探討布地奈德霧化吸入聯(lián)合阿奇霉素對重癥支原體肺炎患兒的臨床療效。方法 選取南陽市第二人民醫(yī)院2011年3月-2017年12月收治的重癥支原體肺炎患兒60例，根據(jù)治療方法分成對照組、觀察組，每組30例。對照組使用阿奇霉素進(jìn)行治療，觀察組使用布地奈德聯(lián)合阿奇霉素進(jìn)行治療。比較兩組的臨床療效、癥狀緩解時間及不良反應(yīng)的發(fā)生情況。結(jié)果 治療結(jié)束后，觀察組臨床療效的總有效率是93.33%，明顯高于對照組的76.67%，差異有統(tǒng)計學(xué)意義（P<0.05）。觀察組患兒的體溫恢復(fù)時間是（2.8±1.1）d，明顯短于對照組的（4.8±1.2）d，差異有統(tǒng)計學(xué)意義（P<0.05）；觀察組患兒的啰音消失時間是（4.2±1.3）d，明顯短于對照組的（6.8±2.1）d，差異有統(tǒng)計學(xué)意義（P<0.05）；觀察組患兒的咳嗽緩解時間是（7.4±1.6）d，明顯短于對照組的（11.4±2.7）d，差異有統(tǒng)計學(xué)意義（P<0.05）。觀察組患兒的不良反應(yīng)發(fā)生率是6.67%，明顯低于對照組的26.67%，差異有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 布地奈德霧化吸入聯(lián)合阿奇霉素對支原體肺炎患兒療效確切，安全可靠，值得臨床應(yīng)用和推廣。

Objective To explore the clinical efficacy on budesonide spray inhalation combined with azithromycin in treatment of children with severe mycoplasma pneumonia. Methods Selected 60 children with severe mycoplasma pneumonia in our hospital from March 2011 to December 2017. All patients were divided into control group and observation group by treatment methods, each group of 30 cases. The control group was treated with azithromycin. The observation group was treated with budesonide combined with azithromycin. The clinical efficacy, symptom relief time and occurrence of adverse reactions of two groups were compared. Results The total effective rate of clinical efficacy in the observation group (93.33%) was significantly higher than that in the control group (76.67%) (P<0.05). Temperature recovery time of observation group (2.8±1.1) d was shorter than that in the control group (4.8±1.2) d (P<0.05). The disappearance time of cough and pulmonary rales of observation group (4.2±1.3) d was shorter than that in the control group (6.8±2.1) d (P<0.05). The cough remission time of observation group (7.4±1.6) d was shorter than that in the control group (11.4±2.7) d (P<0.05). The incidence of adverse events in the observation group (6.67%) was significantly lower than that in the control group (26.67%) (P<0.05). Conclusions The clinical efficacy on budesonide spray inhalation combined with azithromycin in treatment of children with severe mycoplasma pneumonia is good, safe and effective, worthy of clinical application in the promotion.